Investors - Media Releases

Stay Informed

2010 2009 2008 2007 2006 2005 2004 2003

Back to list

January 25, 2010

mondoBIOTECH holding AG: interim financial results for Q3 2009

Stans, Switzerland - January 25, 2010 - mondoBIOTECH holding AG (SIX Swiss Exchange: RARE) is publishing today its unaudited interim financial results for Q3 2009 which will be part of the offering circular which is being published tomorrow, 26 February 2009. The Company realized revenues of CHF 12.17 million in the nine months ended 30 September 2009, mainly resulting from services delivered to third parties as well as some outlicencing fees. This is an increase of +11% in comparison to CHF 10.97 million during the same period in 2008. The overall result of the period was a loss of CHF 7.43 million which is a slight increase of the deficit by 4% when compared to the loss of CHF 7.12 million during the same period in 2008. You can download the unaudited interim financial information of mondoBIOTECH holding AG under: mondoBIOTECH holding AG – Interim financial information 30 September 2009 (unaudited) About Mondobiotech mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent, internet-based biotech research company, discovers drugs for patients suffering from rare and neglected diseases. Mondobiotech has built a continuously growing global community of biologists, biochemists, physicians, patients and patient advocacy organizations who share their passion and skills with Mondobiotech. Together with Mondobiotech, this community is searching for treatments for rare and neglected diseases. For further information please contact: Dr. Yvonne Gunsch-Wegmann, MBA Head of External Relations mondoBIOTECH holding AG Das Kloster Mürgstrasse 18 CH-6370 Stans-Switzerland T+ 41 (0)840 200 010 F+ 41 (0)41 611 09 34 M+41 (0)79 414 39 33 investor@mondobiotech.com www.mondobiotech.com Disclaimer The foregoing release may contain forward-looking statements. The words “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “will”, “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. mondoBIOTECH holding AG may not achieve the plans, intentions or expectations disclosed in its forward-looking statements and prospective investors should not place reliance on mondoBIOTECH holding AG’s forward looking statements. There can be no assurance that results of the activities and results of operations will not differ materially from the expectations. Forward-looking statements are subject to inherent risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying the forward looking statements. Mondobiotech Holding AG is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW. IN PARTICULAR, THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO U.S. PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. ANY NON-COMPLIANCE WITH SUCH RESTRICTIONS MAY RESULT IN AN INFRINGEMENT OF U.S. SECURITIES LAWS. SECURITIES OF MONDOBIOTECH HOLDING AG ARE NOT BEING PUBLICLY OFFERED OUTSIDE OF SWITZERLAND. IN PARTICULAR, THE SECURITIES OF MONDOBIOTECH HOLDING AG HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT THE REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES LAWS. THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS ACCORDING TO ART. 652A OR ART. 1156 OF THE SWISS CODE OF OBLIGATIONS OR ART. 27 ET SEQ. OF THE SIX LISTING RULES. This document is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). The Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this information or any of its contents. The investment decision of any shareholder or investor should only be based on the offering circular prepared by the Company in connection with the Offering. The offering circular (in English language only) can be ordered free of charge from 25 January 2010 at mondoBIOTECH holding AG, Mürgstrasse 18, CH - 6370 Stans, (tel.: +41 (0) 840 200 010, fax: +41 (0) 840 200 011, email: investor@mondobiotech.com). Personal Information This email is from MondoBIOTECH holding AG. The email and any files transmitted with it are intended solely for the use of the individual or entity to which they are addressed. Any unauthorized dissemination or copying of this email or its attachments, is strictly prohibited and may be illegal. If you have received the email in error please delete it from your system. Download the Newsletter in pdf format

Back to list